2022
Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
Abram SV, Roach BJ, Fryer SL, Calhoun VD, Preda A, van Erp TGM, Bustillo JR, Lim KO, Loewy RL, Stuart BK, Krystal JH, Ford JM, Mathalon DH. Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia. Molecular Psychiatry 2022, 27: 2448-2456. PMID: 35422467, PMCID: PMC9135621, DOI: 10.1038/s41380-022-01502-0.Peer-Reviewed Original ResearchConceptsThalamic dysconnectivityHealthy controlsDysconnectivity patternsIllness courseHealthy volunteersN-methyl-D-aspartate (NMDA) receptor hypofunctionResting-state functional magnetic resonance imaging studyHallucination severityEarly illness schizophreniaExcess glutamate releaseGlutamate release inhibitorNMDAR antagonist ketaminePlacebo-controlled studyMagnetic resonance imaging studySub-anesthetic dosesSchizophrenia-like symptomsResonance imaging studyFunctional magnetic resonance imaging studyKetamine infusionGlutamate releaseNMDAR hypofunctionReceptor hypofunctionKetamine effectsThalamic connectivityRelease inhibitor
2008
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.Peer-Reviewed Original ResearchConceptsGlutamatergic systemMood disordersAntidepressant effectsNMDA antagonistsDouble-blind placebo-controlled crossover studyTreatment-resistant major depressive disorderPlacebo-controlled crossover studyGlutamate release inhibitorSignificant antidepressant effectNMDA receptor expressionRecurrent mental illnessSingle intravenous doseMajor depressive disorderPotential novel therapeuticsGlutamatergic abnormalitiesCrossover studyGlutamate releaseIntravenous doseMood stabilizersDepressive disorderReceptor expressionReceptor modulatorsEvidence of alterationsCerebrospinal fluidAMPA potentiators
2007
Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam
Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH. Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam. Alcohol Clinical And Experimental Research 2007, 31: 604-611. PMID: 17374039, DOI: 10.1111/j.1530-0277.2007.00344.x.Peer-Reviewed Original ResearchConceptsAlcohol withdrawal symptomsWithdrawal symptomsActive medicationAlcohol withdrawalGlutamatergic activationEthanol detoxificationAspartate glutamate receptor antagonistGlutamate release inhibitorGlutamate receptor antagonistsMale alcohol-dependent inpatientsAdditional diazepamDiazepam administrationClinical evidenceStandard pharmacotherapyReceptor antagonistAlcohol-dependent inpatientsRelease inhibitorEthanol dependenceAlcohol abstinenceGlutamate receptorsReceptor inhibitorsWithdrawal severityPlaceboMedicationsNew treatments
2001
Quantitative functional imaging of the brain: towards mapping neuronal activity by BOLD fMRI
Hyder F, Kida I, Behar K, Kennan R, Maciejewski P, Rothman D. Quantitative functional imaging of the brain: towards mapping neuronal activity by BOLD fMRI. NMR In Biomedicine 2001, 14: 413-431. PMID: 11746934, DOI: 10.1002/nbm.733.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingNeuronal activityBOLD functional MRIFunctional MRICerebral cortexPharmacological treatmentGlutamate release inhibitorNeuronal glucose oxidationRat cerebral cortexRelease of glutamateRat forepaw stimulation modelFMRI signalsFunctional magnetic resonance imagingQuantitative magnetic resonance imagingBlood oxygenation levelBOLD fMRI studiesEnergy metabolismBOLD fMRI signalMulti-modal magnetic resonance imagingGlutamatergic neuronsRelease inhibitorChannel blockersRat brainOxygen deliveryNeurochemical basisInhibition of Voltage-Dependent Sodium Channels Suppresses the Functional Magnetic Resonance Imaging Response to Forepaw Somatosensory Activation in the Rodent
Kida I, Hyder F, Behar K. Inhibition of Voltage-Dependent Sodium Channels Suppresses the Functional Magnetic Resonance Imaging Response to Forepaw Somatosensory Activation in the Rodent. Cerebrovascular And Brain Metabolism Reviews 2001, 21: 585-591. PMID: 11333369, DOI: 10.1097/00004647-200105000-00013.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging responseSomatosensory activationFunctional magnetic resonance imaging (fMRI) responsesForepaw stimulationLamotrigine treatmentImaging responseGlutamate release inhibitorBOLD fMRI responsesFunctional imaging signalsBOLD fMRI signal changesFMRI signal changesTime-dependent mannerBaseline CBFAbsence of stimulationSomatosensory cortexRelease inhibitorChannel blockersRat cortexNeurotransmitter cycleBlood flow experimentsFMRI responsesBOLD fMRIStimulationLamotrigineTreatment
2000
Effects of Lamotrigine on Behavioral and Cardiovascular Responses to Cocaine in Human Subjects
Winther L, Saleem R, McCance-Katz E, Rosen M, Hameedi F, Pearsall H, Jatlow P, Kosten T, Woods S. Effects of Lamotrigine on Behavioral and Cardiovascular Responses to Cocaine in Human Subjects. The American Journal Of Drug And Alcohol Abuse 2000, 26: 47-59. PMID: 10718163, DOI: 10.1081/ada-100100590.Peer-Reviewed Original ResearchConceptsBlood pressureHeart rateGlutamate release inhibitorEffects of lamotrigineCocaine-dependent volunteersMood States questionnaireLamotrigine pretreatmentAcute pretreatmentCardiovascular responsesRelaxing effectRelease inhibitorIntranasal cocaineStudy daysDrug effectsLamotriginePredetermined time intervalsCocainePlaceboHuman subjectsState QuestionnaireExperimental sessionsSubjectsMood effectsBehavioral responsesSubjective ratings
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply